Mounjaro, Prescribed Thoughtfully. Not Just a Prescription.

Mounjaro is the brand name for tirzepatide, an injectable medication taken once a week. It works by activating two hormone receptors at the same time: GIP and GLP-1. Most GLP-1 medications, like Ozempic or Wegovy, target only the GLP-1 receptor. That dual action is what sets Mounjaro apart, and it's why clinical trials showed particularly strong results for both blood sugar control and weight reduction.

Practically speaking, Mounjaro slows how quickly your stomach empties, reduces appetite, and helps your body respond to insulin more effectively. Patients often describe feeling full sooner and thinking about food less. Those effects are real, and they are the mechanism, not a side effect.

Like all GLP-1 class medications, Mounjaro can cause nausea, especially early on. Starting at a low dose and increasing gradually helps most people tolerate it well. Dr. Gougian goes over this with you before you start, so you know what to expect.

1. 1

   Before you come

   In this case, the evidence is strong. Tirzepatide, the active molecule in Mounjaro, was later approved under the brand name Zepbound specifically for chronic weight management. Weight loss and diabetes share significant biological overlap, and Dr. Gougian's D-ABOM credential reflects the specialized training to make that clinical determination appropriately.

2. 2

   The visit

   If you are coming in specifically for weight loss and Mounjaro is the right fit, she will tell you that. If Zepbound is a better option for your situation, she will explain why. The goal is the right medication for you, not a one-size approach.

3. 3

   Follow-up visits and adjusting your plan

   Mounjaro doses are typically increased gradually, and your follow-up appointments are where we figure out what's working and what needs adjusting. If insurance coverage becomes an issue, we handle prior authorization on your behalf, including appeals if a request gets denied. You're not left to sort that out on your own.

Mounjaro and Zepbound contain the exact same active ingredient: tirzepatide. The difference is FDA approval. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management in adults with obesity or overweight plus a weight-related condition.

Why does this matter? Mostly because of insurance. Some plans cover Mounjaro for diabetes but not for weight loss. Others cover Zepbound for weight loss but not Mounjaro. The coverage depends on your diagnosis, your specific plan, and sometimes the prior authorization criteria your insurer uses.

If you are already on Mounjaro for diabetes and wondering whether switching to Zepbound makes sense, that is a conversation worth having. Dr. Gougian can walk through both options with you at your visit.

Our office is at 6300 Baltimore Ave, University Park, MD 20782, on Route 1 between Hyattsville and College Park, a short drive from Washington, DC and close to Metro’s Green Line.